My Clinical Approach to Polycystic Kidney Disease
Polycystic kidney disease is a condition that accompanies patients and their families for decades. At my urology practice in Rhodes I see patients at every stage: from an incidental ultrasound finding in a young adult to the patient approaching end-stage disease considering transplantation.
My approach centres on early risk stratification — individualised progression prediction using the Mayo Clinic Classification (classes 1A–1E) — to ensure the right treatment is selected for the right patient at the right time.
- Total kidney volume (TKV) assessment by MRI or CT for Mayo classification.
- Blood pressure control with ACE inhibitors or ARBs as the primary nephroprotective strategy.
- Tolvaptan for Mayo ≥1C or GFR >25 ml/min/1.73m² — only after hepatic function assessment.
- Genetic counselling for families — advising first-degree relatives to undergo renal ultrasound screening.
What is Polycystic Kidney Disease
Polycystic kidney disease (PKD) is characterised by the development of multiple fluid-filled cysts in both kidneys. The cysts grow progressively, compressing the functioning renal parenchyma and leading to gradual renal failure.
It must not be confused with simple acquired kidney cysts — which are benign, non-hereditary, and do not cause renal failure.
Two Main Forms
ADPKD (Autosomal Dominant): the common form — manifests in adulthood. ARPKD (Autosomal Recessive): rare, presents in infancy/childhood, more severe prognosis.
Genetics & Epidemiology
ADPKD results from mutations in two genes encoding proteins of the primary cilium:
PKD1 (chromosome 16) — ~85% of cases
Encodes polycystin-1. More severe course — mean age at ESRD ~55 years. Over 1,000 distinct mutations have been described.
PKD2 (chromosome 4) — ~15% of cases
Encodes polycystin-2. Milder course — mean age at ESRD ~74 years. Smaller total kidney volume at any given age.
De novo mutations — ~5–10%
No family history present. Genetic testing is the only route to identification when family history is absent.
Epidemiology: ADPKD occurs in 1 in 400–1,000 births — accounting for ~10% of causes of end-stage renal disease worldwide. No difference in prevalence between sexes.
Symptoms & Clinical Presentation
ADPKD symptoms typically emerge in the 3rd–4th decade of life:
Hypertension
Present in >60% of patients, often preceding overt renal impairment. Caused by activation of the renin-angiotensin system through cystic compression of intrarenal vessels.
Loin & Abdominal Pain
Chronic or acute pain from kidney enlargement, intra-cyst haemorrhage, or cyst infection. Kidneys may become palpable in advanced stages.
Haematuria
Macroscopic haematuria occurs in 35–50% of patients, usually from intra-cyst haemorrhage. Resolves spontaneously in most cases. See: haematuria.
Urinary Tract Infections & Cyst Infection
Increased frequency of UTIs, especially in women. Cyst infection (fever + focal pain) requires prolonged antibiotic therapy with lipophilic antibiotics. See: pyelonephritis.
Kidney Stones
Nephrolithiasis in ~20–30% (calcium oxalate and uric acid stones). See: kidney stones.
Haematuria in PKD: Always Evaluate for Kidney Cancer
New or persistent haematuria in a patient with polycystic kidney disease must be evaluated for kidney cancer — the risk of renal cell carcinoma is slightly elevated. Prompt evaluation is also required for:
- New, sudden, and very severe headache — possible rupture of an intracranial aneurysm.
- Fever with focal loin pain — cyst infection requiring prolonged antibiotic therapy.
- Sudden deterioration in renal function — new precipitating factor or obstruction.
Extra-renal Manifestations
ADPKD is a systemic disease — extra-renal manifestations are clinically significant:
Liver Cysts (~80%)
The most common extra-renal manifestation. Usually asymptomatic. Rarely, large hepatic cysts cause abdominal discomfort or biliary compression.
Intracranial Aneurysms (~10%)
The most life-threatening risk. Brain MRA screening is recommended for patients with a family history of stroke or aneurysm, or in high-risk occupations.
Mitral Valve Prolapse (~25%)
Usually asymptomatic. Rarely causes embolism — cardiology review in patients with a murmur.
Pancreatic / Splenic Cysts
Rarely clinically significant. Incidental findings on CT or MRI.
Diagnosis & Imaging
Diagnosis is based on imaging criteria in combination with family history:
Renal Ultrasound
Primary investigation. Ravine/Pei criteria for ADPKD (number of cysts per kidney per age): ≥2 per kidney at age 15–39, ≥2 per kidney at 40–59, ≥4 per kidney at ≥60. Used for family screening.
CT / MRI of Kidneys
Calculation of total kidney volume (TKV) for Mayo classification and tolvaptan eligibility. MRI is preferred due to absence of radiation — useful for serial monitoring.
Genetic Testing
Molecular analysis of PKD1/PKD2 for families without history or for prenatal/pre-implantation diagnosis. Also useful when family history is absent.
Blood Tests
eGFR, urea, creatinine, electrolytes, uric acid. Serial GFR monitoring to assess rate of progression.
Treatment Options
Treatment aims to slow progression, manage symptoms, and prevent complications:
Blood Pressure Control — Primary Nephroprotection
ACE inhibitors or ARBs are the agents of choice — they not only control blood pressure but also exert nephroprotective (anti-fibrotic) effects. Target: BP <130/80 mmHg. Avoid NSAIDs and nephrotoxic agents.
Tolvaptan — Slowing Progression
Vasopressin V2-receptor antagonist — reduces TKV growth rate by ~50% and slows GFR decline (TEMPO 3:4 trial, Torres 2012). Indicated in ADPKD Mayo ≥1C, age <55, eGFR >25 ml/min/1.73m². Requires regular hepatic function monitoring.
Supportive Measures
High fluid intake (2–3 L/day) to suppress vasopressin. Low-sodium diet. Moderate caffeine. Avoid prolonged immobility. Management of nephrolithiasis if present.
Dialysis & Transplantation
For ESRD. Kidney transplantation is the treatment of choice — outcomes are excellent and the disease does not recur in the graft. Native nephrectomy is required if the kidneys are too large to allow room for the transplant or if recurrent cyst infections occur.
Surgical Management
Surgery in PKD addresses complications rather than the underlying disease:
Laparoscopic / Robotic Cyst Decortication
For large symptomatic cysts unresponsive to conservative treatment. Aim: decompression and pain relief. Limited efficacy when cysts are too numerous.
Infected Cyst Drainage
Under CT or ultrasound guidance for a large infected cyst not responding to antibiotics. Drainage with culture of aspirate.
Nephrectomy Prior to Transplantation
If the native kidneys are too large and leave insufficient space for a transplant, or in the setting of recurrent cyst infections. Laparoscopic or robotic approach preferred.
Management of Nephrolithiasis
ESWL, laparoscopic stone surgery, or PCNL depending on stone size and location. Technically more challenging due to anatomical distortion caused by cysts.
Follow-up & Prognosis
Regular follow-up is an integral component of PKD management:
- Annual eGFR, blood pressure, urinalysis — for all patients.
- Kidney MRI every 1–3 years for TKV assessment and Mayo classification.
- On tolvaptan: liver function tests every 3 months in the first year.
- Echocardiography in patients with a cardiac murmur (rule out MVP).
- Brain MRA in patients with a family history of intracranial aneurysm.
- Family screening: renal ultrasound in first-degree relatives from age 18–20.
Prognosis
Prognosis depends on genotype (PKD1 worse than PKD2) and total kidney volume. The rate of progression is highly variable — many PKD1 patients do not reach ESRD before age 60. With optimal management — ACE inhibitors/ARBs plus tolvaptan where indicated — renal function can be preserved for decades.
Frequently Asked Questions (FAQ)
What is autosomal dominant polycystic kidney disease (ADPKD)?
ADPKD is the most common hereditary kidney disease — occurring in 1 in 400–1,000 people. It is caused by mutations in the PKD1 or PKD2 genes, leading to the formation of multiple cysts in both kidneys that progressively enlarge over decades.
Is polycystic kidney disease hereditary?
ADPKD is inherited in an autosomal dominant pattern — each child of an affected parent has a 50% chance of inheriting the condition. The autosomal recessive form (ARPKD) is rare and presents in childhood. First-degree relatives of affected patients should be screened.
When do symptoms first appear?
In ADPKD, symptoms typically appear in the 3rd–4th decade of life. Hypertension is often the first finding (~60–70% of patients). End-stage renal disease (ESRD) develops at an average age of around 60 years.
Can disease progression be slowed?
Yes. Tolvaptan (a vasopressin V2-receptor antagonist) slows the rate of kidney enlargement and the decline in GFR in patients with rapidly progressive disease. Blood pressure control with ACE inhibitors or ARBs is also essential for nephroprotection.
What is the connection between ADPKD and brain aneurysms?
Approximately 10% of ADPKD patients develop intracranial aneurysms (vs 2–3% in the general population). Brain MRA screening is recommended in patients with a family history of intracranial aneurysm or stroke, or in those with high-risk occupations.
Does polycystic kidney disease require surgery?
Surgery is not the primary treatment for ADPKD. It is considered in selected cases: drainage of large symptomatic cysts, laparoscopic nephrectomy prior to transplantation if kidneys are excessively enlarged, or management of infected cysts.
Can I receive a kidney transplant if I reach end-stage disease?
Yes. Kidney transplantation is the treatment of choice for ESRD in ADPKD — outcomes are excellent and the disease does not recur in the graft. Removal of the native kidneys may be required if they are too large or if recurrent cyst infections occur.
Is there an increased risk of kidney cancer in polycystic kidney disease?
A slightly elevated risk of renal cell carcinoma has been reported — particularly in patients with very large kidneys or extensive cystic disease. New haematuria, sudden severe headache, or rapid cyst enlargement always require prompt evaluation.
Related Topics
Book Your Appointment in Rhodes
Diagnosed with polycystic kidney disease? Risk stratification, Mayo classification, and an individualised management plan are available at the urology practice in Rhodes.
References – Sources
- EAU Guidelines on Chronic Kidney Disease 2024 — uroweb.org
- Torres VE, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367:2407–18 (TEMPO 3:4).
- KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD 2024.
- Cornec-Le Gall E, et al. Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease. Am J Hum Genet 2018;102:832–844.
- Chapman AB, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2012;7:479–486.
Medical Review
Dr. Marinos Vasilas, Urologist – Andrologist
Dr. Marinos Vasilas runs a private urology practice in Rhodes with expertise in hereditary kidney disease management, polycystic kidney disease, and laparoscopic/robotic nephrectomy. He follows the EAU Guidelines 2024.
View full profile
